[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630719":3},{"organization":4,"outcomesModule":7,"designInfo":22,"detailedDescription":21,"studyPopulation":25,"armGroups":26,"interventions":40,"overallOfficials":21,"centralContacts":46,"locations":55,"responsibleParty":80,"collaborators":83,"id":92,"slug":21,"hasResults":93,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":93,"sex":99,"minAge":100,"maxAge":21,"enrollmentInfo":101,"targetDuration":21,"studyType":104,"phases":21,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":58,"whyStopped":21,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"Heinrich-Heine University, Duesseldorf","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":21},[9,13],{"measure":10,"description":11,"timeFrame":12},"CTC detection","Detection of circulating tumor cells (CTCs) in the peripheral blood","Time of enrollment (BL)",{"measure":14,"description":15,"timeFrame":12},"ctDNA detection","Detection of circulating tumor DNA (ctDNA) in serum",[17],{"measure":18,"description":19,"timeFrame":20},"CTC mutation profile","Mutations in oncogenes and tumor suppressor genes","Time of CTC analysis (BL)",null,{"allocation":21,"interventionModel":21,"interventionModelDescription":21,"primaryPurpose":21,"observationalModel":23,"timePerspective":24,"maskingInfo":21},"COHORT","PROSPECTIVE","The study population will include patients with paraneoplastic neurological syndromes (PNS) and matched tumor patients without PNS.",[27,32,36],{"label":28,"type":21,"description":29,"interventionNames":30},"PNS+T","Patients with paraneoplastic neurological syndromes (PNS) and high- or intermediate-risk or GAD65-antibodies with a detectable tumor",[31],"Diagnostic Test: CTC & ctDNA analysis",{"label":33,"type":21,"description":34,"interventionNames":35},"PNS w\u002Fo T","PNS patients with high- or intermediate-risk or GAD65-antibodies without detectable tumor",[31],{"label":37,"type":21,"description":38,"interventionNames":39},"T w\u002Fo PNS","Tumor patients without PNS",[31],[41],{"type":42,"name":43,"description":44,"armGroupLabels":45,"otherNames":21},"DIAGNOSTIC_TEST","CTC & ctDNA analysis","Analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in the peripheral blood",[33,28,37],[47,52],{"name":48,"role":49,"phone":50,"phoneExt":21,"email":51},"Nico Melzer, MD","CONTACT","+49-(0)211-81-04170","nico.melzer@med.uni-duesseldorf.de",{"name":53,"role":49,"phone":50,"phoneExt":21,"email":54},"Saskia Räuber, MD","SaskiaJanina.Raeuber@med.uni-duesseldorf.de",[56],{"facility":57,"status":58,"city":59,"state":21,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf","RECRUITING","Düsseldorf","40225","Germany","DE",{"type":64,"coordinates":65},"Point",[66,67],6.77927,51.22319,{"lat":67,"lon":66},[70,71,72,74,76,78],{"name":48,"role":49,"phone":50,"phoneExt":21,"email":51},{"name":53,"role":49,"phone":50,"phoneExt":21,"email":54},{"name":48,"role":73,"phone":21,"phoneExt":21,"email":21},"PRINCIPAL_INVESTIGATOR",{"name":53,"role":75,"phone":21,"phoneExt":21,"email":21},"SUB_INVESTIGATOR",{"name":77,"role":75,"phone":21,"phoneExt":21,"email":21},"Nikolas H. Stoecklein, MD",{"name":79,"role":75,"phone":21,"phoneExt":21,"email":21},"Johannes Fischer, MD",{"type":73,"investigatorFullName":81,"investigatorTitle":82,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"PD Dr. Nico Melzer","Chief Consultant Neurologist",[84,86,88,90],{"name":85,"class":6},"University of Regensburg",{"name":87,"class":6},"Universität Münster",{"name":89,"class":6},"Erasmus Medical Center",{"name":91,"class":6},"Medical University of Graz","100630719",false,"NCT07491328","Liquid Biopsy in Paraneoplastic Neurological Syndromes","Liquid Biopsy in Paraneoplastic Neurological Syndromes With High- and Intermediate-Risk Antibodies","LiB-PNS","Inclusion Criteria:\n\n* Patients with paraneoplastic neurological syndromes (PNS) and high- or intermediate-risk or GAD65-antibodies or\n* Patients with peripheral tumors without PNS\n\nExclusion Criteria:\n\n* Age below 18 years at the time of inclusion.\n* Any mental condition impairing the capacity to provide informed consent.\n* Presence of contraindications to DLA.","ALL","18 Years",{"count":102,"type":103},60,"ESTIMATED","OBSERVATIONAL","The main objective of the study is to assess whether circulating tumor cells (CTCs) can be detected in the peripheral blood of patients with paraneoplastic neurological syndromes (PNS) by diagnostic leukapheresis (DLA) combined with the CELLSEARCH® System during clinical routine workup. If CTCs can be identified, a detailed molecular genetic analysis will be performed to characterize mutations in oncogenes and tumor suppressor genes. In addition, the study aims to analyze cell-free DNA (cfDNA) in serum of patients.\n\nIndividuals with PNS and high- or intermediate-risk or GAD65-antibodies with a detectable tumor (PNS+T), PNS patients with high- or intermediate-risk or GAD65-antibodies without detectable tumor (PNS w\u002Fo T), and matched tumor patients without PNS (T w\u002Fo PNS) will be included in the study.",[107],"Paraneoplastic Neurological Syndromes",[109,110,111],"Circulating tumor cells (CTCs)","Circulating tumor DNA (ctDNA)","Diagnostic leukapheresis (DLA)","2026-03-18",{"date":114,"type":115},"2026-03-24","ACTUAL",{"date":117,"type":115},"2023-05-20",{"date":119,"type":103},"2030-12-30",{"name":5,"class":6},1]